Abstract
The objectives were to study the expression of very late antigen (VLA)-4, melanoma cell adhesion molecule-1 (MCAM-1) and activated leukocyte cell adhesion molecule (ALCAM) on CD4+ T cells during natalizumab treatment and to investigate the association with disease activity. We find that subgroups of autoreactive T cells are retained in peripheral blood, in particular MOG-reactive CD4+ T cells expressing MCAM-1. The expression of MCAM-1 or ALCAM on CD4+ T cells was, however, not clearly associated with disease activity (clinical or MRI) during natalizumab treatment. We confirm upregulation of MCAM-1 on CD4+ T cells during natalizumab treatment while VLA-4 is downregulated.
Original language | English |
---|---|
Article number | 577085 |
Journal | Journal of Neuroimmunology |
Volume | 337 |
ISSN | 0165-5728 |
DOIs | |
Publication status | Published - 2019 |
Keywords
- Adhesion molecules
- ALCAM
- Blood-brain barrier
- MCAM-1
- Multiple sclerosis
- Natalizumab